| Drug Name |
Cobimetinib |
| Drug ID |
BADD_D00513 |
| Description |
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. |
| Indications and Usage |
For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EE02 |
| DrugBank ID |
DB05239
|
| KEGG ID |
D10405
|
| MeSH ID |
C574276
|
| PubChem ID |
16222096
|
| TTD Drug ID |
D0FJ9I
|
| NDC Product Code |
50242-717 |
| UNII |
ER29L26N1X
|
| Synonyms |
cobimetinib | (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone | Cotellic | GDC-0973 | XL518 |
